Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Research and Innovation Action · Running

PvSTATEM Serological Testing and Treatment for P. Vivax: from a Cluster-randomised Trial in Ethiopia and Madagascar to a Mobile-technology Supported Intervention

Coordinator
Institut Pasteur, France
Runs
1 October 2022 to 30 September 2027
Status
Running
EU funding
€7.3m
Total cost
€7.3m
Partners
9 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101057665

What the project is doing

In the project's own words, from its summary on CORDIS.

P. vivax is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or and the treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated.

Aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on Plasmodium vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, we will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions.

We aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa. We expect to have a significant effect in reducing morbidity and improving health. We will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.

Topics

Who is involved

OrganisationCityCountryRole
Institut PasteurParisFranceCoordinator
The Walter and Eliza Hall Institute of Medical Research Public Companylimited by GuaranteeParkvilleAustraliaAssociatedpartner
Foundation for Innovative New DiagnosticsGeneveSwitzerlandParticipant
Armauer Hansen Research InstituteAddis AbabaETParticipant
University of GalwayGalwayIrelandParticipant
Medea SRLMassa MsItalyParticipant
Institut Pasteur de MadagascarAntananarivoMGParticipant
Politechnika WarszawskaWarszawaPolandParticipant
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI